Sandoz

ZARXIO

Manufacturer:

Sandoz

Zarxio HCPCS:

Q5101

HCPCS Code Descriptor:

Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram

Category:

Q Code

Zarxio NDCs:

61314-0326-10, 61314-0318-10, 61314-0326-01, 61314-0318-01

Primary Type:

Oncology Biosimilar Colony Stimulating Factor

Generic/Specialty Status:

Single-Source

Route of Administration:

Injection

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Zarxio:

ZARXIO is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Sandoz and administered via the Injection route of administration. The Q Code: Q5101 is aligned to the drug ZARXIO.

Zarxio (filgrastim) is an artificial version of a natural substance that is made in your body and is used to aid the production of white blood cells. Zarxio is administered via subcutaneous injection or an intravenous infusion for roughly 15 to 30 minutes. Zarxio is a biosimilar to its reference product Neupogen (J1442). Patient assistance programs for this medication are offered through Sandoz.

ACCESS PRICING AND MORE BY REGISTERING

Q5101 Added Date:

July 1, 2015

Q5101 Effective Date:

January 1, 2023

Q5101 Termination Date:

HCPCS Active

Zarxio billing and coding information can be found through Sandoz at the link below:
Zarxio patient assistance information can be found through Sandoz One Source Commercial Co-Pay Program at the URL: https://www.zarxio.com/patient/support-services
ZARXIO prescribing information can be found at the link below:
Information regarding ZARXIO’s side effects can be found at MedlinePlus